ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

HPV16+ Cancers Market to 2030 - Featuring Cue Biopharma, GlaxoSmithKline and Transgene Among Others - ResearchAndMarkets.com

September 15, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Sep 15, 2021--

The “Human Papillomavirus 16 - positive (HPV16+) Cancers - Market Insight, Epidemiology and Market Forecast - 2030” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the HPV 16+ Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The HPV 16+ Cancer market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HPV 16+ Cancer symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current HPV 16+ Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

ADVERTISEMENT

Companies Mentioned

  • Advaxis, Inc.
  • BioNTech
  • Cue Biopharma
  • GlaxoSmithKline
  • Hookipa Pharma
  • Innovio Pharma
  • Invectys
  • ISA Pharmaceuticals
  • Merck
  • PDS Biotechnology
  • Precigen
  • Regeneron Pharmaceuticals
  • Roche Pharma AG
  • Transgene
  • Vaccibody AS

Scope of the Report

  • The report covers the descriptive overview of HPV 16+ Cancer, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the HPV 16+ Cancer epidemiology and treatment in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for HPV 16+ Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the HPV 16+ Cancer market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global HPV 16+ Cancer market

Reasons to Buy

ADVERTISEMENT

  • The report will help in developing business strategies by understanding trends shaping and driving the HPV 16+ Cancer market
  • To understand the future market competition in the HPV 16+ Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for HPV 16+ Cancer in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for HPV 16+ Cancer market
  • To understand the future market competition in the HPV 16+ Cancer market

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. HPV16+ Cancer Market Overview at a Glance

3.1. Market Share (%) Distribution of HPV16+ Cancer in 2018

3.2. Market Share (%) Distribution of HPV16+ Cancer in 2030

4. Executive Summary of HPV16+ Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Risk Factors

5.4. Molecular Mechanisms of HPV

5.5. Malignances associated with HPV

5.6. HPV and Cancer Progression

5.7. Diagnosis

5.8. Biomarkers

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumption and Rationale

6.3. 7MM Total Incident Patient Population of HPV induced Cancer

6.4. The United States

6.4.1. Incident Cases of HPV induced Cancer in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Incident Cases of HPV induced Cancer in Germany

6.5.2. France

6.5.2.1. Incident Cases of HPV induced Cancer in France

6.5.3. Italy

6.5.3.1. Incident Cases of HPV induced Cancer in Italy

6.5.4. Spain

6.5.4.1. Incident Cases of HPV16+ Cancer in Spain

6.5.5. United Kingdom

6.5.5.1. Incident Cases of HPV induced Cancer in the UK

6.6. Japan

6.6.1. Incident Cases of HPV induced Cancer in Japan

7. Treatment and Management

7.1. HPV Vaccines

8. Organizations contributing towards HPV16+ Cancer

9. Patient Journey

10. Case Reports

11. Marketed Products

11.1. Gardasil: Merck

11.1.1. Product Description

11.1.2. Mechanism of action

11.1.3. Regulatory Milestones

11.1.4. Side effects of Gardasil

11.1.5. Product Profile

11.2. Gardasil 9: Merck

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Safety and Efficacy of Gardasil 9

11.2.4. Side effects of Gardasil 9

11.2.5. Product Profile

11.3. Cervarix: GlaxoSmithKline

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Safety and Efficacy of Cervarix

11.3.4. Side effects of Cervarix

11.3.5. Product Profile

12. Emerging Therapies

13. HPV16+ Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of HPV16+ Cancer in the 7MM

14. Market Outlook

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Market Access and Reimbursement

20. Appendix

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/z0asqs

View source version on businesswire.com:https://www.businesswire.com/news/home/20210915005982/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 09/15/2021 01:43 PM/DISC: 09/15/2021 01:43 PM

http://www.businesswire.com/news/home/20210915005982/en